Products for Research Use Only
RegisterLogin

LDE225

CAT: 0013-GTR19160653-01Size: 200 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19160653-01Size:200 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LDE225 (NVP-LDE225; Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. (In Vitro) :The IC50 values for Sonidegib (NVP-LDE225) for the major human CYP450 drug metabolizing enzymes is greater than 10 μM. Sonidegib (LDE225), a small molecule, clinically investigated SMO inhibitor, used alone and in combination with Nilotinib, inhibits the Hh pathway in CD34+ chronic phase (CP) -chronic myeloid leukaemia (CML) cells, reducing the number and self-renewal capacity of CML leukaemia stem cell (LSC) . Sonidegib interacts directly with SMO, in a similar fashion to cyclopamine, to reduce expression of downstream Hh signaling targets. Primary CD34+ CP-CML cells are cultured in serum free media (SFM) ±Sonidegib for 6, 24 and 72 hours (h) . At 72 h, while there is variability between the biological samples, GLI1 is significantly downregulated following exposure to Sonidegib (10 nM; 0.78-fold and 100 nM; 0.73-fold, respectively (p<0.01) . (In Vivo) :Sonidegib (NVP-LDE225) is a weak base with a measured pKa of 4.2 and exhibits relatively poor aqueous solubility. In the subcutaneous Ptch+/-p53-/- medulloblastoma allograft mouse model, Sonidegib demonstrates dose-related antitumor activity after 10 days of oral administration of a suspension of the diphosphate salt. At a dose of 5 mg/kg/day qd, Sonidegib significantly inhibits tumor growth, corresponding to a T/C value of 33% (p<0.05 as compared to vehicle controls) . When dosed at 10 and 20 mg/kg/day qd, Sonidegib affords 51 and 83% regression, respectively. Bone marrow cells and spleen cells from a subset of treated mice are transplanted into secondary recipient mice. Transplantation of either bone marrow (BM) or spleen cells from mice treated with Sonidegib (LDE225) +Nilotinib results in reduced white cell count (WCC) and reduces leukaemia development in secondary recipients compared to Sonidegib or Nilotinib alone.
CAS Number
956697-53-3
Product Name Alternative
NVP-LDE225, Erismodegib
Purity
>98% (HPLC)
Solubility
Ethanol: 97 mg/mL (199.79 mM) ; DMSO: 97 mg/mL (199.79 mM)
Smiles
C[C@@H]1CN (C[C@@H] (O1) C) C2=NC=C (C=C2) NC (=O) C3=CC=CC (=C3C) C4=CC=C (C=C4) OC (F) (F) F
Molecular Formula
C26H26F3N3O3
Molecular Weight
485.5
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.

Alternative Products

CatalogName
E1KS2151LDE225 (NVP-LDE225)
MBS577279LDE225 (NVP-LDE225, Erismodegib)
M16829-01LDE225
A10520-100LDE225 100mg
B2266-200LDE225 (NVP-LDE225,Erismodegib)
A10520-25LDE225 (NVP-LDE225, Sonidegib) 25mg
MBS385025-01LDE225 (NVP-LDE225, Sonidegib)
MBS385026-01LDE225 Diphosphate
A10520-5LDE225 5mg
A12774-5LDE225 Diphosphate 5mg

Popular Products